Journal
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
Volume 12, Issue 1, Pages -Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.14309/ctg.0000000000000293
Keywords
-
Categories
Funding
- excellence initiative VASCage (Centre for Promoting Vascular Health in the Ageing Community)
- R&D K-Centre (COMET programme-Competence Centers for Excellent Technologies) - Austrian Ministry for Transport, Innovation and Technology
- Austrian Ministry for Digital and Economic Affairs
- federal state Tyrol
- federal state Salzburg
- federal state Vienna
- Austrian Science Fund (FWF) [FP33070-B]
Ask authors/readers for more resources
COVID-19 patients show elevated levels of fecal neopterin, especially in those experiencing gastrointestinal symptoms, indicating an inflammatory immune response in the gastrointestinal tract.
INTRODUCTION: Coronavirus disease (COVID-19) has spread from Wuhan, China, and become a worldwide pandemic. Most patients display respiratory symptoms but up to 50% report gastrointestinal symptoms. Neopterin is a surrogate marker for viral inflammation, and its production by macrophages is driven by interferon-gamma. METHODS: We measured fecal neopterin in 37 hospitalized COVID-19 patients not requiring intensive care measures and 22 healthy controls. RESULTS: Fecal neopterin was elevated in stool samples from COVID-19 patients compared with that in samples from healthy controls. Especially, patients reporting gastrointestinal symptoms exhibited increased fecal neopterin values. DISCUSSION: COVID-19 is associated with an inflammatory immune response in the gastrointestinal tract.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
